Irisin Levels in Patients with MAFLD
Author Information
Author(s): Shen Chenglu, Wu Kaihan, Ke Yani, Zhang Qin, Chen Shuaihang, Li Qicong, Ruan Yuting, Yang Xudan, Liu Shan, Hu Jie
Primary Institution: The First Clinical Medical College of Zhejiang Chinese Medical University
Hypothesis
This study explores the relevance between circulating irisin levels and metabolic dysfunction-associated fatty liver disease (MAFLD).
Conclusion
Circulating irisin levels are significantly lower in patients with MAFLD compared to healthy controls.
Supporting Evidence
- Fifteen case-control studies were included in the analysis.
- Circulating irisin levels were significantly lower in the MAFLD group compared to healthy controls.
- Subgroup analyses showed lower irisin levels in Asian populations and in patients over 50 years old.
Takeaway
Irisin is a substance in our body that helps with metabolism, and people with a liver disease called MAFLD have less of it than healthy people.
Methodology
This study is a systematic review and meta-analysis that included 15 case-control studies.
Potential Biases
Potential bias due to the predominance of studies from a single region and the variability in ELISA kits used.
Limitations
The majority of studies were from Asia, and the sample size was limited to 15 articles.
Participant Demographics
The average age of participants ranged from 33 to 68 years, with a mix of male and female participants.
Statistical Information
P-Value
p<0.05
Confidence Interval
[-1.93, -0.14]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website